Tacrolimus solution - Bay Pharma
Alternative Names: TACRO-SkinLatest Information Update: 22 Apr 2022
At a glance
- Originator Bay Pharma
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antiglaucomas; Antipsoriatics; Antirheumatics; Eye disorder therapies; Lactones; Macrolides; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 22 Apr 2022 No development reported - Phase-III for Psoriasis in France (Topical) (EudraCT2019-000215-92)
- 03 Aug 2020 Bay Pharma completes the ScaTAC phase III trial in Psoriasis in France (Topical) (EudraCT2019-000215-92)
- 16 Jul 2019 Chemical structure information added